Hartaj Singh
Stock Analyst at Oppenheimer
(1.44)
# 3,499
Out of 4,987 analysts
111
Total ratings
40.38%
Success rate
-10.95%
Average return
Main Sectors:
Stocks Rated by Hartaj Singh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Upgrades: Outperform | $30 → $37 | $17.64 | +109.75% | 13 | Jul 29, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $925 → $900 | $591.60 | +52.13% | 15 | Apr 29, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $132 → $125 | $112.94 | +10.68% | 15 | Apr 25, 2025 | |
| VRTX Vertex Pharmaceuticals | Downgrades: Perform | n/a | $388.28 | - | 17 | Dec 19, 2024 | |
| SPRB Spruce Biosciences | Downgrades: Perform | n/a | $8.95 | - | 6 | Dec 11, 2024 | |
| ATXS Astria Therapeutics | Maintains: Outperform | $26 → $28 | $7.50 | +273.33% | 6 | Nov 14, 2024 | |
| UTHR United Therapeutics | Maintains: Outperform | $575 → $600 | $405.59 | +47.93% | 7 | Oct 31, 2024 | |
| MRNA Moderna | Downgrades: Perform | n/a | $25.95 | - | 8 | Sep 13, 2024 | |
| CLLS Cellectis | Maintains: Outperform | $11 → $10 | $3.22 | +210.56% | 5 | Jun 12, 2024 | |
| BMEA Biomea Fusion | Maintains: Outperform | $70 → $60 | $2.00 | +2,900.00% | 5 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 | $1.71 | +427.86% | 4 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $2.36 | +1,594.92% | 4 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $5.27 | +317.46% | 1 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $16 | $3.41 | +369.21% | 3 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $650 | $1.69 | +38,361.54% | 1 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $30 | $18.75 | +60.00% | 1 | Jan 26, 2018 |
Sarepta Therapeutics
Jul 29, 2025
Upgrades: Outperform
Price Target: $30 → $37
Current: $17.64
Upside: +109.75%
Regeneron Pharmaceuticals
Apr 29, 2025
Maintains: Outperform
Price Target: $925 → $900
Current: $591.60
Upside: +52.13%
Gilead Sciences
Apr 25, 2025
Maintains: Outperform
Price Target: $132 → $125
Current: $112.94
Upside: +10.68%
Vertex Pharmaceuticals
Dec 19, 2024
Downgrades: Perform
Price Target: n/a
Current: $388.28
Upside: -
Spruce Biosciences
Dec 11, 2024
Downgrades: Perform
Price Target: n/a
Current: $8.95
Upside: -
Astria Therapeutics
Nov 14, 2024
Maintains: Outperform
Price Target: $26 → $28
Current: $7.50
Upside: +273.33%
United Therapeutics
Oct 31, 2024
Maintains: Outperform
Price Target: $575 → $600
Current: $405.59
Upside: +47.93%
Moderna
Sep 13, 2024
Downgrades: Perform
Price Target: n/a
Current: $25.95
Upside: -
Cellectis
Jun 12, 2024
Maintains: Outperform
Price Target: $11 → $10
Current: $3.22
Upside: +210.56%
Biomea Fusion
May 30, 2024
Maintains: Outperform
Price Target: $70 → $60
Current: $2.00
Upside: +2,900.00%
Apr 23, 2024
Maintains: Outperform
Price Target: $9
Current: $1.71
Upside: +427.86%
Mar 8, 2024
Maintains: Outperform
Price Target: $40
Current: $2.36
Upside: +1,594.92%
Jan 5, 2024
Initiates: Outperform
Price Target: $22
Current: $5.27
Upside: +317.46%
Sep 13, 2023
Maintains: Outperform
Price Target: $31 → $16
Current: $3.41
Upside: +369.21%
Nov 1, 2018
Initiates: Outperform
Price Target: $650
Current: $1.69
Upside: +38,361.54%
Jan 26, 2018
Maintains: Outperform
Price Target: $24 → $30
Current: $18.75
Upside: +60.00%